Palisade Bio (PALI) Non-Current Receivables (2016 - 2018)
Palisade Bio (PALI) reported Non-Current Receivables of $298238.0 for Q4 2018, down 18.39% year-over-year from $365456.0 in Q4 2017, and up 2.72% on a QoQ basis from $290354.0 in Q3 2018.
Palisade Bio (PALI) has 3 years of Non-Current Receivables data on file, last reported at $298238.0 in Q4 2018.
- Quarterly Non-Current Receivables fell 18.39% year-over-year to $298238.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $298238.0 (down 18.39% YoY) and the FY2018 annual result came in at $298238.0, down 18.39% from the prior year.
- Non-Current Receivables rose to $298238.0 in Q4 2018 per PALI's latest filing, from $290354.0 in the prior quarter.
- Across five years, Non-Current Receivables topped out at $424240.0 in Q4 2016 and bottomed at $290354.0 in Q3 2018.
- The 3-year median for Non-Current Receivables is $360815.0 (2017), against an average of $362131.7.
- The widest annual swing landed in 2017, when Non-Current Receivables retreated 13.86%; it then fell 18.48% in 2018.
- Tracing PALI's Non-Current Receivables over 3 years: stood at $424240.0 in 2016, then declined by 13.86% to $365456.0 in 2017, then decreased by 18.39% to $298238.0 in 2018.
- Per Business Quant, the three latest PALI Non-Current Receivables figures stand at $298238.0 (Q4 2018), $290354.0 (Q3 2018), and $343281.0 (Q2 2018).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 298,238.00 |
| Sep 30, 2018 | 290,354.00 |
| Jun 30, 2018 | 343,281.00 |
| Mar 31, 2018 | 334,303.00 |
| Dec 31, 2017 | 365,456.00 |
| Sep 30, 2017 | 356,174.00 |
| Jun 30, 2017 | 402,965.00 |
| Mar 31, 2017 | 392,840.00 |
| Dec 31, 2016 | 424,240.00 |
| Sep 30, 2016 | 413,466.00 |